A chemically modified thrombolytic agent for reduced intracerebral bleeding risk

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KWON, Young (Nova Southeastern University, Pharmaceutical Sciences, College of Pharmacy, Fort Lauderdale, United States)
  • Co-author(s): Young M Kwon: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
    Wael Mahdi: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
    Gerardo Ramos: Department of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, United States
  • Abstract:

    Methods

    The modified tPA was synthesized via a specific thiolation method.  The bioactivity of the modified tPA was evaluated by an indirect chromogenic assay.  A monolayer culture of HBMEC was used as a model component of the human BBB to evaluate the effect of the treatments (native tPA and the modified tPA) on the production of MMP-9 and the..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login